Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets

@inproceedings{Gasperini2010EmergingOT,
  title={Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets},
  author={Claudio Gasperini and Serena Ruggieri and Carlo Pozzilli},
  booktitle={Therapeutics and clinical risk management},
  year={2010}
}
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) that represents one of the first causes of neurological disability in young adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been demonstrated. According to this evidence in the last 15 years different treatments acting on the immune system have been developed. Current disease-modifying drugs (DMDs) for MS require regular and frequent parenteral administration and… CONTINUE READING
3 Citations
40 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 40 references

CLARITY study group. A placebo controlled Trial of Oral Cladribine for Multiple Sclerosis

  • G Giovannoni, S Cook, G Comi
  • N Engl J Med. 2010 Jan 20. [Epub ahead of print]
  • 2010
Highly Influential
5 Excerpts

Vermersch P .The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

  • TP Leist
  • 2007
Highly Influential
17 Excerpts

Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis

  • MR DiMatteo
  • 2009

Similar Papers

Loading similar papers…